PP_1170x120_10-25-21

Pfizer-BioNTech COVID-19 Vaccine in children 6 months to under 5 years of age

Pfizer-BioNTech COVID-19 vaccine offers strong immune response for kids

Pfizer-BioNTech COVID-19 vaccine offers strong immune response for kids

NEW YORK — Pfizer Inc. and BioNTech SE announced Monday topline safety, immunogenicity and vaccine efficacy data from a Phase 2/3 trial evaluating a third 3-µg dose of the Pfizer-BioNTech COVID-19 Vaccine in children 6 months to under 5 years of age. Following a third dose in this age group, the vaccine was found to

Adheris Health